Arrowhead Pharmaceuticals Financial Statements (ARWR)
|
|
|
|
Report date
|
|
|
22.11.2021 |
28.11.2022 |
29.11.2023 |
26.11.2024 |
25.11.2025 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
138.3 |
243.2 |
240.7 |
3.55 |
829.4 |
|
622.0 |
|
Operating Income, bln rub |
|
|
-149.0 |
-178.5 |
-205.0 |
-601.1 |
98.3 |
|
-221.9 |
|
EBITDA, bln rub |
? |
|
-132.6 |
-162.3 |
-175.7 |
-561.5 |
164.8 |
|
-162.0 |
|
Net profit, bln rub |
? |
|
-140.8 |
-176.1 |
-205.3 |
-599.5 |
-1.63 |
|
-300.9 |
|
|
OCF, bln rub |
? |
|
171.3 |
-136.1 |
-153.9 |
-462.9 |
179.6 |
|
-36.3 |
|
CAPEX, bln rub |
? |
|
23.6 |
52.8 |
176.7 |
141.5 |
22.7 |
|
14.6 |
|
FCF, bln rub |
? |
|
147.7 |
-188.9 |
-330.6 |
-604.3 |
156.9 |
|
-50.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
279.1 |
411.3 |
433.2 |
586.0 |
731.1 |
|
837.5 |
|
Cost of production, bln rub |
|
|
0.000 |
10.4 |
12.5 |
18.6 |
0.000 |
|
6.37 |
|
R&D, bln rub |
|
|
199.0 |
288.5 |
342.3 |
489.2 |
607.2 |
|
681.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
18.3 |
32.4 |
89.4 |
|
92.4 |
|
|
Assets, bln rub |
|
|
710.1 |
691.9 |
765.6 |
1 140 |
1 385 |
|
2 268 |
|
Net Assets, bln rub |
? |
|
408.8 |
398.5 |
271.3 |
185.4 |
466.1 |
|
614.0 |
|
Debt, bln rub |
|
|
25.5 |
81.6 |
383.5 |
851.9 |
366.3 |
|
1 373 |
|
Cash, bln rub |
|
|
367.8 |
376.4 |
403.6 |
681.0 |
919.4 |
|
1 784 |
|
Net debt, bln rub |
|
|
-342.2 |
-294.8 |
-20.1 |
171.0 |
-553.1 |
|
-410.8 |
|
|
Ordinary share price, rub |
|
|
62.4 |
33.1 |
26.9 |
19.4 |
34.5 |
|
26.2 |
|
Number of ordinary shares, mln |
|
|
103.7 |
105.4 |
107.3 |
119.8 |
133.8 |
|
142.4 |
|
|
Market cap, bln rub |
|
|
6 477 |
3 484 |
2 883 |
2 320 |
4 613 |
|
3 726 |
|
EV, bln rub |
? |
|
6 135 |
3 190 |
2 863 |
2 491 |
4 060 |
|
3 315 |
|
Book value, bln rub |
|
|
395 |
387 |
261 |
177 |
459 |
|
608 |
|
|
EPS, rub |
? |
|
-1.36 |
-1.67 |
-1.91 |
-5.00 |
-0.01 |
|
-2.11 |
|
FCF/share, rub |
|
|
1.42 |
-1.79 |
-3.08 |
-5.05 |
1.17 |
|
-0.36 |
|
BV/share, rub |
|
|
3.81 |
3.67 |
2.43 |
1.48 |
3.43 |
|
4.27 |
|
|
EBITDA margin, % |
? |
|
-95.9% |
-66.7% |
-73.0% |
-15 813% |
19.9% |
|
-26.0% |
|
Net margin, % |
? |
|
-101.9% |
-72.4% |
-85.3% |
-16 882% |
-0.20% |
|
-48.4% |
|
FCF yield, % |
? |
|
2.28% |
-5.42% |
-11.5% |
-26.0% |
3.40% |
|
-1.37% |
|
ROE, % |
? |
|
-34.5% |
-44.2% |
-75.7% |
-323.3% |
-0.35% |
|
-49.0% |
|
ROA, % |
? |
|
-19.8% |
-25.4% |
-26.8% |
-52.6% |
-0.12% |
|
-13.3% |
|
|
P/E |
? |
|
-46.0 |
-19.8 |
-14.0 |
-3.87 |
-2 829 |
|
-12.4 |
|
P/FCF |
|
|
43.8 |
-18.4 |
-8.72 |
-3.84 |
29.4 |
|
-73.2 |
|
P/S |
? |
|
46.8 |
14.3 |
12.0 |
653.4 |
5.56 |
|
5.99 |
|
P/BV |
? |
|
16.4 |
9.01 |
11.0 |
13.1 |
10.0 |
|
6.13 |
|
EV/EBITDA |
? |
|
-46.3 |
-19.7 |
-16.3 |
-4.44 |
24.6 |
|
-20.5 |
|
Debt/EBITDA |
|
|
2.58 |
1.82 |
0.11 |
-0.30 |
-3.36 |
|
2.54 |
|
|
R&D/CAPEX, % |
|
|
844.3% |
546.6% |
193.7% |
345.8% |
2 679% |
|
4 680% |
|
|
CAPEX/Revenue, % |
|
|
17.0% |
21.7% |
73.4% |
3 984% |
2.73% |
|
2.34% |
|
| Arrowhead Pharmaceuticals shareholders |
